BPAX Key Stats
- BioSante Pharmaceuticals, Inc. Reports First Quarter Financial Results Business Wire May 10
- BIOSANTE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Finan... May 10
- BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Special Meetings of St... May 8
- Huge Potential But Tough Entry For Female Sexual Dysfunction Drugs May 7
- 4 Bio Stocks to Buy Today May 1
- Ceregene Reports Disappointing Top-Line Data From Parkinson's Disease Phase 2b S... Apr 19
- Ceregene Reports Data From Parkinson's Disease Phase 2b Study PR Newswire Apr 19
- BioSante Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. Announce New Merger... Apr 13
- BioSante Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. Announce New Merger... Apr 12
- BIOSANTE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitiv... Apr 12
BPAX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Biosante Pharmaceuticals is down 58.79% over the last year vs S&P 500 Total Return up 28.68%, Repros Therapeutics up 98.72%, and Teva Pharmaceutical Industries up 3.39%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for BPAX
Pro Report PDF for BPAX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download BPAX Pro Report PDF
Pro Strategies Featuring BPAX
Did Biosante Pharmaceuticals make it into our Pro Portfolio Strategies?